- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 207/40 - Pyrrolidines-2, 5 diones
Détention brevets de la classe C07D 207/40
Brevets de cette classe: 138
Historique des publications depuis 10 ans
|
5
|
13
|
14
|
13
|
6
|
5
|
5
|
5
|
7
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Alkermes Pharma Ireland Limited | 254 |
16 |
| Cv6 Therapeutics (NI) Limited | 33 |
10 |
| Hangzhou DAC Biotech Co., Ltd | 113 |
5 |
| Uniwersytet Jagiellonski | 278 |
4 |
| Warszawski Uniwersytet Medyczny | 65 |
4 |
| Allergan, Inc. | 2170 |
3 |
| Chevron Oronite Company LLC | 596 |
3 |
| Mainstream Pine Products, LLC | 58 |
3 |
| Novartis AG | 10279 |
2 |
| The Regents of the University of California | 20694 |
2 |
| Syngenta Participations AG | 1530 |
2 |
| Hewlett-Packard Development Company, L.P. | 25246 |
2 |
| University of Southern California | 2128 |
2 |
| Afton Chemical Corporation | 493 |
2 |
| Dana-Farber Cancer Institute, Inc. | 2657 |
2 |
| Instituto Mexicano Del Petroleo | 206 |
2 |
| ISP Investments Inc. | 445 |
2 |
| Iteos Therapeutics | 18 |
2 |
| Janssen Sciences Ireland UC | 162 |
2 |
| Korea University Research and Business Foundation | 3259 |
2 |
| Autres propriétaires | 66 |